Compare VOC & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | FEMY |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 37.2M |
| IPO Year | N/A | 2021 |
| Metric | VOC | FEMY |
|---|---|---|
| Price | $3.56 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 129.9K | ★ 381.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.50% | N/A |
| EPS Growth | N/A | ★ 8.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | N/A | $147.19 |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $2.44 | $0.31 |
| 52 Week High | $3.74 | $1.76 |
| Indicator | VOC | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 42.05 |
| Support Level | $2.73 | $0.47 |
| Resistance Level | N/A | $0.58 |
| Average True Range (ATR) | 0.20 | 0.04 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 71.91 | 30.35 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.